Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Trial of LEVI-04 in Knee Osteoarthritis
2021-006540-28Phase 2Completed
- Sponsor
- Levicept
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing LEVI-04 multiple doses with Placebo (2 arms). Primary endpoint: Primary: Change in WOMAC Pain subscale to week 17. Started Apr 2022; status: completed.
02
Drugs
LEVI-04
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2021-006540-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006540-28.